NASDAQ:BMRN BioMarin Pharmaceutical - BMRN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $117.27 +0.29 (+0.25%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$116.81▼$117.7750-Day Range$88.51▼$117.2752-Week Range$70.73▼$117.77Volume1.22 million shsAverage Volume1.54 million shsMarket Capitalization$21.75 billionP/E Ratio279.21Dividend YieldN/APrice Target$120.12 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability BioMarin Pharmaceutical MarketRank™ ForecastAnalyst RatingModerate Buy2.79 Rating ScoreUpside/Downside2.4% Upside$120.12 Price TargetShort InterestHealthy3.68% of Float Sold ShortDividend StrengthN/ASustainability-2.93Upright™ Environmental ScoreNews Sentiment0.55Based on 23 Articles This WeekInsider TradingSelling Shares$10.38 M Sold Last QuarterProj. Earnings Growth164.77%From $0.88 to $2.33 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.46 out of 5 starsMedical Sector191st out of 1,054 stocksPharmaceutical Preparations Industry88th out of 517 stocks 2.4 Analyst's Opinion Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.79, and is based on 11 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $120.12, BioMarin Pharmaceutical has a forecasted upside of 2.4% from its current price of $117.27.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.68% of the float of BioMarin Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently decreased by 35.33%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioMarin Pharmaceutical has received a 35.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Galsulfase", "Laronidase", and "Cerliponase alfa" products. See details.Environmental SustainabilityThe Environmental Impact score for BioMarin Pharmaceutical is -2.93. Previous Next 3.1 News and Social Media Coverage News SentimentBioMarin Pharmaceutical has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for BioMarin Pharmaceutical this week, compared to 4 articles on an average week.Search Interest38 people have searched for BMRN on MarketBeat in the last 30 days. This is an increase of 443% compared to the previous 30 days.MarketBeat Follows10 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have sold 3,199.54% more of their company's stock than they have bought. Specifically, they have bought $314,469.00 in company stock and sold $10,376,018.00 in company stock.Percentage Held by InsidersOnly 1.75% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions96.26% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 164.77% in the coming year, from $0.88 to $2.33 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is 279.21, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 119.79.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is 279.21, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 93.44.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 5.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioMarin Pharmaceutical (NASDAQ:BMRN) StockBioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.Read More Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address BMRN Stock News HeadlinesJanuary 28, 2023 | americanbankingnews.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Jeffrey Robert Ajer Sells 49,000 SharesJanuary 28, 2023 | americanbankingnews.comWilliam Blair Weighs in on BioMarin Pharmaceutical Inc.'s Q4 2022 Earnings (NASDAQ:BMRN)January 29, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 27, 2023 | americanbankingnews.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Short Interest UpdateJanuary 26, 2023 | americanbankingnews.comBioMarin Pharmaceutical (NASDAQ:BMRN) PT Raised to $132.00January 25, 2023 | americanbankingnews.comBioMarin Pharmaceutical Inc. to Post FY2022 Earnings of $0.82 Per Share, Cantor Fitzgerald Forecasts (NASDAQ:BMRN)January 25, 2023 | americanbankingnews.comFY2022 EPS Estimates for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Increased by AnalystJanuary 25, 2023 | americanbankingnews.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $119.00 Consensus Price Target from AnalystsJanuary 29, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 21, 2023 | americanbankingnews.comJean Jacques Bienaime Sells 10,000 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) StockJanuary 20, 2023 | americanbankingnews.comInsider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CFO Sells 2,500 Shares of StockJanuary 19, 2023 | americanbankingnews.comInsider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Sells 10,000 Shares of StockJanuary 19, 2023 | americanbankingnews.comBioMarin Pharmaceutical (NASDAQ:BMRN) Research Coverage Started at Canaccord Genuity GroupJanuary 11, 2023 | markets.businessinsider.com6 Analysts Have This to Say About Biomarin PharmaceuticalJanuary 10, 2023 | bloomberg.comBioMarin’s Gene Therapy Cuts Annual Bleeds by 80% Over 3 YearsJanuary 9, 2023 | finance.yahoo.comDeals, data kick off biotech's big JPM WeekJanuary 7, 2023 | finance.yahoo.comEarnings growth outpaced the 29% return delivered to BioMarin Pharmaceutical (NASDAQ:BMRN) shareholders over the last yearJanuary 4, 2023 | finance.yahoo.comBioMarin's (BMRN) Voxzogo Expanded Label Filing Accepted by EMAJanuary 4, 2023 | finance.yahoo.comBioMarin to Present at 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, at 10:30 am PT /1:30 pm ET, in San Francisco, CAJanuary 3, 2023 | finance.yahoo.comEuropean Medicines Agency Validates Application for Extension of Indication for VOXZOGO® (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2January 2, 2023 | thestreet.comBioMarin (BMRN) Stock Surges on Takeover SpeculationDecember 28, 2022 | finance.yahoo.comBioMarin Pharmaceutical Inc. (BMRN)December 27, 2022 | thestreet.comBioMarin Pharmaceutical (BRMN) Stock Rises After CEO Appears on Jim Cramer's 'Mad Money'December 23, 2022 | finance.yahoo.comBiotech Stock Finds Favor Among Mutual Fund ManagersDecember 17, 2022 | seekingalpha.comBMRN BioMarin Pharmaceutical Inc.December 17, 2022 | seekingalpha.comBioMarin Pharmaceutical - Solutions For Rare IllnessesDecember 2, 2022 | finance.yahoo.comWhy Is Horizon Therapeutics (HZNP) Up 38.3% Since Last Earnings Report?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address BMRN Company Calendar Last Earnings10/26/2021Today1/29/2023Next Earnings (Estimated)2/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:BMRN CUSIP09061G10 CIK1048477 Webwww.bmrn.com Phone(415) 506-6700Fax415-382-7889Employees3,045Year Founded1997Price Target and Rating Average Stock Price Forecast$120.12 High Stock Price Forecast$200.00 Low Stock Price Forecast$83.00 Forecasted Upside/Downside+2.4%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$0.42 Trailing P/E Ratio279.21 Forward P/E Ratio133.26 P/E GrowthN/ANet Income$-64,080,000.00 Net Margins4.18% Pretax Margin5.01% Return on Equity2.50% Return on Assets1.81% Debt Debt-to-Equity Ratio0.24 Current Ratio5.15 Quick Ratio3.54 Sales & Book Value Annual Sales$1.85 billion Price / Sales11.78 Cash Flow$0.86 per share Price / Cash Flow135.65 Book Value$23.26 per share Price / Book5.04Miscellaneous Outstanding Shares185,470,000Free Float182,228,000Market Cap$21.75 billion OptionableOptionable Beta0.36 Social Links Key ExecutivesJean-Jacques BienaiméChairman & Chief Executive OfficerBrian R. MuellerChief Financial Officer & Executive VP-FinanceEduardo E. von PervieuxChief Information OfficerHenry J. FuchsPresident-Worldwide Research & DevelopmentKevin EgganGroup VP, Head-Research & Early DevelopmentKey CompetitorsAlnylam PharmaceuticalsNASDAQ:ALNYUnited TherapeuticsNASDAQ:UTHRIonis PharmaceuticalsNASDAQ:IONSRegeneron PharmaceuticalsNASDAQ:REGNVertex PharmaceuticalsNASDAQ:VRTXView All CompetitorsInsiders & InstitutionsNatixis Advisors L.P.Sold 13,239 shares on 1/27/2023Ownership: 0.034%Rice Hall James & Associates LLCBought 13,377 shares on 1/27/2023Ownership: 0.019%D.B. Root & Company LLCSold 299 shares on 1/27/2023Ownership: 0.002%Tokio Marine Asset Management Co. Ltd.Sold 703 shares on 1/26/2023Ownership: 0.012%Comerica BankBought 305 shares on 1/26/2023Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions BMRN Stock - Frequently Asked Questions Should I buy or sell BioMarin Pharmaceutical stock right now? 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BMRN shares. View BMRN analyst ratings or view top-rated stocks. What is BioMarin Pharmaceutical's stock price forecast for 2023? 14 analysts have issued 12-month target prices for BioMarin Pharmaceutical's shares. Their BMRN share price forecasts range from $83.00 to $200.00. On average, they expect the company's stock price to reach $120.12 in the next year. This suggests a possible upside of 2.4% from the stock's current price. View analysts price targets for BMRN or view top-rated stocks among Wall Street analysts. How have BMRN shares performed in 2023? BioMarin Pharmaceutical's stock was trading at $103.49 at the beginning of 2023. Since then, BMRN stock has increased by 13.3% and is now trading at $117.27. View the best growth stocks for 2023 here. Are investors shorting BioMarin Pharmaceutical? BioMarin Pharmaceutical saw a decline in short interest in January. As of January 15th, there was short interest totaling 6,700,000 shares, a decline of 35.3% from the December 31st total of 10,360,000 shares. Based on an average daily trading volume, of 1,560,000 shares, the short-interest ratio is presently 4.3 days. Currently, 3.7% of the company's shares are sold short. View BioMarin Pharmaceutical's Short Interest. When is BioMarin Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023. View our BMRN earnings forecast. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its quarterly earnings data on Tuesday, October, 26th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.05. The biotechnology company earned $408.74 million during the quarter, compared to analyst estimates of $435.29 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 2.50% and a net margin of 4.18%. BioMarin Pharmaceutical's quarterly revenue was down 14.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.29 EPS. What guidance has BioMarin Pharmaceutical issued on next quarter's earnings? BioMarin Pharmaceutical updated its FY 2022 earnings guidance on Wednesday, November, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.06 billion-$2.16 billion, compared to the consensus revenue estimate of $2.12 billion. What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO? 228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX). What is BioMarin Pharmaceutical's stock symbol? BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN." Who are BioMarin Pharmaceutical's major shareholders? BioMarin Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional investors include Manning & Napier Group LLC (0.47%), Assenagon Asset Management S.A. (0.38%), Scout Investments Inc. (0.30%), DNB Asset Management AS (0.25%), Allspring Global Investments Holdings LLC (0.23%) and Natixis Advisors L.P. (0.03%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, David E I Pyott, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Michael G Grey, Richard A Meier, V Bryan Lawlis and Willard H Dere. View institutional ownership trends. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioMarin Pharmaceutical's stock price today? One share of BMRN stock can currently be purchased for approximately $117.27. How much money does BioMarin Pharmaceutical make? BioMarin Pharmaceutical (NASDAQ:BMRN) has a market capitalization of $21.75 billion and generates $1.85 billion in revenue each year. The biotechnology company earns $-64,080,000.00 in net income (profit) each year or $0.42 on an earnings per share basis. How many employees does BioMarin Pharmaceutical have? The company employs 3,045 workers across the globe. How can I contact BioMarin Pharmaceutical? BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The official website for the company is www.bmrn.com. The biotechnology company can be reached via phone at (415) 506-6700, via email at ir@bmrn.com, or via fax at 415-382-7889. This page (NASDAQ:BMRN) was last updated on 1/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.